Piper Sandler Reaffirms Overweight Rating for Health Catalyst (NASDAQ:HCAT)

Health Catalyst (NASDAQ:HCAT)‘s stock had its “overweight” rating reaffirmed by research analysts at Piper Sandler in a research note issued to investors on Tuesday,Benzinga reports. They presently have a $12.00 price target on the stock, up from their prior price target of $11.00. Piper Sandler’s price objective would indicate a potential upside of 38.73% from the company’s previous close.

HCAT has been the subject of several other reports. Citigroup boosted their price objective on shares of Health Catalyst from $9.00 to $10.50 and gave the company a “buy” rating in a research report on Wednesday, November 13th. JPMorgan Chase & Co. upped their price objective on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research report on Wednesday, September 4th. Royal Bank of Canada lifted their target price on Health Catalyst from $8.00 to $9.00 and gave the company a “sector perform” rating in a research report on Thursday, November 7th. Evercore ISI raised their price target on shares of Health Catalyst from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Tuesday, October 8th. Finally, Stephens lifted their price target on shares of Health Catalyst from $7.00 to $9.00 and gave the company an “equal weight” rating in a report on Thursday, November 14th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Health Catalyst currently has a consensus rating of “Moderate Buy” and an average price target of $11.79.

Health Catalyst Stock Performance

HCAT opened at $8.65 on Tuesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. Health Catalyst has a 52-week low of $5.42 and a 52-week high of $11.41. The firm has a market cap of $526.34 million, a P/E ratio of -6.41 and a beta of 1.32. The business’s fifty day moving average is $8.13 and its 200-day moving average is $7.30.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The firm had revenue of $76.40 million for the quarter, compared to analyst estimates of $76.27 million. Health Catalyst had a negative return on equity of 7.51% and a negative net margin of 26.20%. The company’s quarterly revenue was up 3.5% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.22) earnings per share. Sell-side analysts expect that Health Catalyst will post -0.35 EPS for the current fiscal year.

Insider Buying and Selling at Health Catalyst

In related news, insider Kevin Lee Freeman sold 7,500 shares of the business’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total value of $54,150.00. Following the sale, the insider now owns 255,881 shares of the company’s stock, valued at $1,847,460.82. The trade was a 2.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Daniel Lesueur sold 8,137 shares of the firm’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $7.58, for a total value of $61,678.46. Following the transaction, the chief operating officer now directly owns 140,108 shares of the company’s stock, valued at approximately $1,062,018.64. This represents a 5.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 34,068 shares of company stock worth $257,555. 2.50% of the stock is currently owned by company insiders.

Institutional Trading of Health Catalyst

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HCAT. Price T Rowe Associates Inc. MD boosted its stake in shares of Health Catalyst by 6.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 49,746 shares of the company’s stock valued at $375,000 after purchasing an additional 2,831 shares during the last quarter. SG Americas Securities LLC bought a new stake in Health Catalyst during the second quarter valued at $187,000. Nepsis Inc. grew its holdings in Health Catalyst by 8.3% during the 2nd quarter. Nepsis Inc. now owns 1,253,080 shares of the company’s stock worth $8,007,000 after acquiring an additional 95,686 shares during the period. Nisa Investment Advisors LLC raised its position in shares of Health Catalyst by 461.0% in the 2nd quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after acquiring an additional 5,232 shares in the last quarter. Finally, Perfromance Wealth Partners LLC acquired a new position in shares of Health Catalyst in the 2nd quarter valued at about $64,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.